Overview
Most metabolic-research compounds in this catalog are incretin-system agonists (GLP-1, GIP, and glucagon-receptor ligands) and related signaling molecules. The published literature studies them for metabolic and body-composition research endpoints. This guide describes how the compound is characterized and what that research covers. It is not usage guidance and makes no claim about outcomes from use.
A selective growth-hormone secretagogue (GHRP) studied for GH release with minimal effect on cortisol or prolactin.
Evidence at a glance: Preclinical (animal) evidence
The cited evidence here is preclinical animal-model work, with limited or no human-trial data. Read the research profile accordingly.
Molecular identity
- Molecular formula
- C38H49N9O5
- Molecular weight
- 711.85 g/mol
- CAS number
- 170851-70-4
- Amino acids
- 5
- Appearance
- White lyophilized powder
- Purity (HPLC)
- 99.2%
Researched mechanism
Ghrelin/GHS receptor agonism stimulating pulsatile GH release with high selectivity.
Described as a mechanism characterized in the literature, not an effect you should expect from use.
What the published research shows
Selective GH release characterized in preclinical work.
Every citation states its study type and population, so preclinical data is never presented as human-efficacy evidence.
How it compares
| Versus | Attribute | Note |
|---|---|---|
| CJC-1295 | Mechanism | GHRP vs GHRH; commonly co-studied. |
| Hexarelin | Selectivity | Ipamorelin is more selective (less cortisol/prolactin) than hexarelin. |
Reconstitution
Concentration math only: adding bacteriostatic water to the vial gives the resulting mg/mL shown below. This is not usage guidance.
| Vial | Bacteriostatic water | Concentration |
|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL |
| 10 mg | 2 mL | 5 mg/mL |
Storage & stability
| State | Temperature | Duration |
|---|---|---|
| Lyophilized (unopened) | -20°C | 24 months |
| Reconstituted | 2–8°C | up to 4 weeks |
Common questions
What makes it 'selective'?+
Research describes GH release with minimal cortisol/prolactin impact relative to other GHRPs.
